

Special Issue

Genomics of Gynaecological Cancer Defining Current and Future Treatment Options

Message from the Guest Editors

Next-generation sequencing has enabled individual gynaecological cancers (ovarian, fallopian tube, endometrial (uterine), cervical, vulval or vaginal cancer) to be segregated into different molecular subtypes. Despite molecular differences, subtypes may be treated with the same standard therapies, often with poor responses. Targeted drugs have been developed for specific molecular alterations and have had a positive impact in the treatment of some types of cancer. With the increased publication of genomics and pre-clinical precision medicine studies in this area, hopefully, matched clinical trials will prove successful and treatment options for these rare diseases with often poor prognoses will improve. This Special Issue welcomes papers on the genomics of gynaecological cancers (preclinical, clinical and real-world), with a focus on the improvement of the current standard treatments through application of new targeted therapies including immunotherapy based on molecular data.

Guest Editors

Dr. Holly Barker

Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne, Australia; and the Department of Medical Biology, The University of Melbourne, Melbourne, Australia

Dr. Susana Banerjee

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London SW3 6JJ, UK

Deadline for manuscript submissions

closed (31 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/74258

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)